OCULAR THERAPEUTIX, INC
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
About Ocular Therapeutix
Pharmaceutical Preparations, SIC 2834
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for eye diseases and conditions using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX. Its primary commercial product is DEXTENZA, which is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. In addition, the company develops investigational therapies including AXPAXLI, a product candidate in clinical evaluation for wet age-related macular degeneration and non-proliferative diabetic retinopathy, as well as OTX-TIC for open-angle glaucoma and ocular hypertension.
The company conducts its operations and research activities in the United States and maintains corporate collaborations, including a licensing agreement with AffaMed Therapeutics Limited covering territories in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Southeast Asian nations. Ocular Therapeutix operates separate single-site manufacturing facilities for commercial inventory and clinical product candidates, and its principal executive offices are located in Bedford, Massachusetts.
Summary of the business section of Ocular Therapeutix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OCULAR THERAPEUTIX, INC
- Headquarters
- Bedford, MA
- Address
- 14 Crosby Drive, 3rd Floor 01730
- Phone
- (781) 357-4000
- Website
- ocutx.com
- Employees
- 325, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- OCUL
- Exchange
- Nasdaq
- IPO date
- Jul 25, 2014
- Shares outstanding
- 220M, Jul 31, 2026
- Public float
- $1.60B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1393434
- CUSIP
- 67576A100
- ISIN
- US67576A1007
- LEI
- 529900ABAWFXOHSIHG03
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Pravin Dugel | See Remarks, Director | 3,270,332 |
| Donald Notman | Chief Operating Officer | 366,529 |
| Peter Kaiser | Chief Development Officer | 264,378 |
| Jeffrey S. Heier | Chief Scientific Officer | 318,326 |
| Sanjay Nayak | Chief Strategy Officer | 326,898 |
| Jason Shand Robins | Chief Financial Officer | 68,097 |
| Nadia Waheed | Chief Medical Officer | 300,079 |
| David Wayne Robinson | Global CCO | 136,000 |
| Todd Anderman | Chief Legal Officer | 152,468 |
| Namrata Saroj | Chief Business Officer | 254,620 |
| Steve Lawrence Meyers | Chief Commercial Officer | 217,628 |
| Richard L. Lindstrom Md | Director | 304,492 |
| Merilee Raines | Director | 60,933 |
| Charles M. Warden | Director | 100,464 |
| Leslie J. Williams | Director | 65,433 |
| Seung Suh Hong | Director | 60,933 |
| Adrienne L. Graves | Director | 64,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dugel | $35.95M | $57.53M | $3.52M | $59 | $120 |
| FY2024 Dugel | $18.57M | $9.65M | $6.61M | $41 | $91 |
| FY2024 Mattessich | $8.78M | $5.83M | $6.61M | $41 | $91 |
| FY2023 Mattessich | $3.28M | $1.03M | $1.41M | $22 | $92 |
| FY2022 Mattessich | $4.10M | -$2.09M | $1.51M | $14 | $89 |
| FY2021 Mattessich | $7.10M | -$4.22M | $3.61M | $34 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 325 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 25, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 21, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 2, 2009 | Name change | Name changed from I-THERAPEUTIX INC to OCULAR THERAPEUTIX, INC |